A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)

Trial Profile

A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2018

At a glance

  • Drugs Poziotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms POZITIVE20-1
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 23 Apr 2018 According to a Spectrum Pharmaceuticals media release, the company is planning study centre expansion in the U.S. and other countries.
    • 10 Apr 2018 According to a Spectrum Pharmaceuticals media release, as enrollment in MD Andersons phase 2 study (NCT03066206) nears completion, patient enrolling will begin soon in this ongoing Spectrums Phase 2 study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top